Zipalertinib after surgery for early-stage lung cancer with uncommon EGFR mutations
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to completely remove your lung cancer.
- Your cancer has a specific uncommon EGFR gene change (like an exon 20 insertion or others such as G719X, L861Q, or S768I).
- Your cancer was stage IB, IIA, IIB, or IIIA (or IIIB with certain lymph node involvement).
- You have fully recovered from surgery and any chemotherapy you had after surgery.
- You are able to swallow pills and have no serious digestive problems.
- You have not had radiation therapy for this lung cancer.
- You have no history of interstitial lung disease (a type of lung scarring) or active lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests zipalertinib, a targeted pill for people with non-small cell lung cancer that has an atypical EGFR gene change. It is given after standard treatment like surgery or radiation to help prevent the cancer from coming back.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
This trial gives access to an investigational drug called zipalertinib for people with a specific type of advanced lung cancer (EGFR exon 20 insertion) who have already tried chemotherapy. The goal is to see if the drug can help control the cancer when other treatments have stopped working.
This trial tests a new targeted pill (zipalertinib) combined with standard chemotherapy (carboplatin and pemetrexed) before surgery for early-stage lung cancer with specific EGFR mutations. It aims to shrink the tumor and potentially improve outcomes after surgery.
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.